LL-37 and Tesamorelin Interaction

Synergistic
Mechanism-based 47% confidence

LL-37 and Tesamorelin have a synergistic interaction with 47% confidence. LL-37 and Tesamorelin work through complementary pathways. Growth hormone signaling supports tissue repair processes. A well-established combination in recovery protocols. These compounds primarily affect different organ systems.

Compound Profiles

LL-37

Human Cathelicidin | Antimicrobial Peptide

Provides direct antimicrobial activity through membrane disruption, promotes wound healing by enhancing keratinocyte migration and angiogenesis, and modulates immune responses without systemic exposure when used topically..

Half-life: Short (rapid proteolytic degradation) Typical dose: 0.5-1.6 mg/mL topical gel or 100-150 mcg injectable immune, healing
View full profile

Tesamorelin

GHRH Analog | Visceral Fat Reduction

Subcutaneous injection provides optimal bioavailability for GHRH receptor binding and pulsatile GH release stimulation, selectively targeting visceral adipose tissue while sparing subcutaneous fat..

Half-life: 26-38 minutes Typical dose: 1.4-2mg daily (FDA-approved: 2mg for HIV lipodystrophy) growth hormone, weight loss
ghrh receptor carcinogenic riskinsulin disruptingteratogenic
View full profile

Combined Organ Load

Blood Vessels
low
GI Tract
low
Pituitary
low

Frequently Asked Questions

Can I take LL-37 with Tesamorelin?

Yes, LL-37 and Tesamorelin can generally be taken together. LL-37 and Tesamorelin work through complementary pathways. Growth hormone signaling supports tissue repair processes. A well-established combination in recovery protocols.

Is LL-37 and Tesamorelin safe together?

Based on pharmacological analysis, this combination is considered synergistic. No critical safety flags identified for this pair.

What are the interactions between LL-37 and Tesamorelin?

LL-37 and Tesamorelin work through complementary pathways. Growth hormone signaling supports tissue repair processes. A well-established combination in recovery protocols. This assessment has 47% confidence and is inferred from pharmacological mechanism analysis.

How should I time LL-37 and Tesamorelin?

LL-37 has a half-life of Short (rapid proteolytic degradation) and Tesamorelin has a half-life of 26-38 minutes. No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.

Check this pair in the full Interaction Checker Full comparison: LL-37 vs Tesamorelin

This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.